Schrodinger has co-founded Tectora Therapeutics, a $55 million Series A-backed biotech built to develop two of its own AI-designed drug candidates for immunology and inflammation.
Novo Nordisk has named AWS its preferred cloud and AI partner and opened a co-innovation hub in London, using tools like Amazon Bio Discovery and Bedrock to try to compress the path from drug target to first human dose, part of a broader wave of pharma-hyperscaler AI deals.
MyFitnessPal launched an AI Nutrition Coach built on its Cal AI acquisition, just as a NUTRITION 2026 study found AI calorie-photo apps average a 345-calorie estimation error.
Ono Pharmaceutical has partnered with Aitia to use causal AI 'digital twins' to identify new drug targets for hard-to-treat neurological diseases, joining a wave of 2026 pharma-AI deals betting that modeling cause and effect — not just correlation — can finally move the needle on brain disease drug discovery.
A new market analysis shows AI-assisted pathology moving from pilot projects to routine clinical use, spotlighting PathAI's $165 million funding round and its expanded Labcorp partnership — even as independent clinical-outcome trials won't report results until 2029.
Leica Biosystems announced August 11, 2026 it won FDA clearance for what it calls the first standalone AI-assisted quality control tool for digital pathology slide scanning, aimed at catching scanning defects before they corrupt downstream AI diagnostics.
A WHO Europe forum on September 1, 2026 argued that health AI progress should be judged by the strength of governance frameworks rather than deployment speed, building on a 2025 dialogue that surveyed experts from 105 countries.
Advocate Health is deploying AI startup Lind's platform to automatically screen cancer patients for clinical trial eligibility, aiming to fix a system in which only about 5% of eligible patients nationally ever enroll in a trial.
A randomized trial of an AI tool co-developed by Mayo Clinic and Bayesian Health found earlier palliative care referrals cut 90-day hospital readmissions by 28%, offering rare outcome-level proof for a predictive hospital AI system.
Deep Origin said in August 2026 that its hybrid physics-and-AI drug discovery platform achieved a 31% hit rate against a cancer immunotherapy enzyme, nearly 100 times higher than typical machine-learning-only screening approaches.